A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Tag: anticoagulant

  • Apixaban (Eliquis): Good News

    Eliquis (Apixaban) is one of the 4 promising new oral anticoagulants that (a) do not require routine monitoring of its anticoagulant effect and (b) work independently of the vitamin K pathway.

  • Eliquis (Apixaban) – Good News

    Eliquis (Apixaban) is one of the 4 promising new oral “blood thinners” that (a) do not require monitoring of its “blood thinning” (anticoagulant) effect, i.e. do not require INR monitoring, and (b) do not interfere with vitamin K in the diet, i.e. patients can eat what they want.

  • DVT and PE: How Long to Treat With Anticoagulants?

    Explanation for Patients The complex topic of “Length of Anticoagulant Treatment” for patients with VTE  is being addressed in a blog entry written for patients, found on the Clot Connect patient education blog (here). For the Health Care Professional Well respected treatment guidelines exist [ref 1,2].

  • DVT and PE: How Long to Treat with “Blood Thinners”

    What Kind of Clot did You Have? If you have had a blood clot in your legs or your lung (pulmonary embolism=PE), you will wonder how long you should stay on a “blood thinner”. The decision depends on a number of factors which will be discussed below.

  • Apixaban (Eliquis®) – Another New Oral Anticoagulant

    Good news.  Another one of the new oral anticoagulants in development,  Apixaban (Eliquis®), has moved forward.  On May 20th, 2011, the European Medicines Agency (EMA) approved Eliquis® for DVT prevention after orthopedic surgery (hip and knee replacement) in the 27 countries of the European Community. In the U.S., however, Eliquis® is still some way away from getting FDA approval

  • Dental Work on Warfarin

    A number of dental procedures can be done safely withouthaving to discontinue warfarin. A clinically helpful table is can be found here: Dental procedures and Warfarin (from ref 1).

  • Xarelto® – Good News

    Summary Good news. A major study published in December 2010 in the  New England Journal of Medicine (NEJM) shows that the new oral “blood thinner” Xarelto® (=Rivaroxaban) is (a) as safe and effective as warfarin in patients with acute DVT, and (b) is quite effective in preventing recurrent venous thromboembolism if taken longer-term, with an…

  • Xarelto® – Good News

    Summary Good news. A major study published in December 2010 in the prestigious New England Journal of Medicine (NEJM) shows that the new oral “blood thinner” Xarelto® (=Rivaroxaban) is (a) as safe and effective as warfarin in patients with acute deep vein thrombosis (DVT), and (b) is quite effective in preventing recurrent blood clots (DVT…